Postpartum Continuous Glucose Monitoring for Type 2 Diabetes Risk in Women With Gestational Diabetes Mellitus

What this Trial Is About

Researchers are studying the use of continuous glucose monitoring CGM shortly after delivery to predict the long-term risk of developing Type 2 Diabetes Mellitus in patients diagnosed with gestational diabetes. This pilot study focuses on how well CGM works compared to standard tests like the 2-hour glucose tolerance test and HbA1c test postpartum. The study is sponsored by the University of California, Los Angeles and aims to gather detailed blood sugar data to improve risk assessment. Participants will receive a continuous glucose monitor within two hours after delivery and will wear it for 24 hours to collect detailed blood sugar information. After 24 hours, participants will be asked to remove the device themselves. The study includes completing two surveys about their experience with the CGM device at 1 to 3 months postpartum and again at 12 to 14 months postpartum. During the study, researchers will compare CGM data collected immediately postpartum to traditional glucose tests taken later. They will also assess patient satisfaction with the CGM device during follow-up surveys. The total participation involves wearing the device for one day after delivery and completing surveys over the following year. The study will monitor clinical efficacy and patient experience to understand CGMs potential role in predicting diabetes risk after gestational diabetes.

Postpartum Continuous Glucose Monitoring for Type 2 Diabetes Mellitus Risk Evaluation in Patients With Gestational Diabetes Mellitus: POSTPOD Trial